Compare ZVIA & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | PYPD |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 107.0M |
| IPO Year | 2021 | 2014 |
| Metric | ZVIA | PYPD |
|---|---|---|
| Price | $0.94 | $6.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $3.67 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 451.5K | 193.8K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $161,259,000.00 | N/A |
| Revenue This Year | $9.55 | N/A |
| Revenue Next Year | $6.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $0.96 | $3.50 |
| 52 Week High | $2.75 | $7.15 |
| Indicator | ZVIA | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 66.10 |
| Support Level | N/A | $4.26 |
| Resistance Level | $1.52 | $7.15 |
| Average True Range (ATR) | 0.13 | 0.52 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 0.53 | 62.63 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.